RUNX1 and central nervous system cancer: In GBM, knockdown of RUNX1 in U-87 MG cells inhibits the angiogenesis of human umbilical vein endothelial cells, and a p38 MAPK inhibitor (SB203580) reduces RUNX1 expression levels; thus, RUNX1 may promote angiogenesis in gliomas through activation of the p38 MAPK signaling pathway [17].